# Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

> **NCT00323115** · PHASE2 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 11 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **BIOLOGICAL:** Autologous Dendritic Cell
- **DRUG:** Temozolomide
- **PROCEDURE:** Radiotherapy
- **BIOLOGICAL:** Dendritic Cell Vaccine

## Key facts

- **NCT ID:** NCT00323115
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-04
- **Final completion:** 2013-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323115, "Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00323115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*